Over the past years, in collaboration with other companies, Nipro has acquired and developed a portfolio of products for the endovascular, interventional cardiology, and interventional radiology markets that we will now represent in Europe. Our products are an initial offering that aim to help with myocardial infarctions (heart attacks) and thrombotic events (clotting).
Our commitment at Nipro is, and has always been, to innovate and provide affordable care worldwide. This remains our focus, and hence, we are developing in fields that touch our hearts closely. Nipro Vascular will be a focused division dedicated to helping healthcare professionals assess the severity of a patient’s disease, as well as guide their choices for the best therapies. Our imaging system Makoto™ Intravascular Imaging System uses intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) to provide a window inside the arteries of patients. Plus, physicians will also be able to assess the immediate accuracy and effectiveness of their chosen treatment to maximize the long-term outcomes for each patient.
We present;
With the innovative products that we are now marketing in Europe, diagnosing patients has become a reliable procedure for interventional cardiologists. Our tools have been developed hand in hand with field physicians and exist to solve the major hurdles that appear when trying to assess lesion morphology, measure lesions for accurate therapy selection, and confirm that the procedure will provide the maximum long-term outcomes with the least risk of MACE (major adverse cardiovascular events).
With this new solution, we aim to provide the European market with a reliable portfolio of products that will both help patients who suffer from myocardial infarctions (heart attacks) and thrombotic events (clotting) to be easily diagnosed, as well as aid interventional cardiologists to apply the appropriate therapies.
